Who should not take GLP-1s GLP-1s in all forms are unsuitable for people who: are pregnant or breastfeeding do not meet the eligibility criteria have a family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2) Medical Perspective Patients with needle phobia, a preference for pill-based routines, or good adherence to oral administration guidelines may be better suited to oral GLP-1 formulations like semaglutide (Rybelsus, Wegovy), which can enhance treatment acceptance and potentially offer strong glycemic or weight control
Orforglipron (Foundayo) is a daily tablet that works on the GLP-1 pathway to reduce appetite, while Mounjaro is a weekly injection that targets both GLP-1 and GIP, making it more potent
The right choice depends on convenience, side effect tolerance, clinical suitability, and how well the medicine fits into your routine
Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the global GLP-1 Analogues market
Continue reading Which GLP-1 medication is most effective for weight loss
Because it targets GLP-1, GIP, and glucagon pathways, side effects and monitoring needs may be more complex than single-pathway medications
